A scientifically focused, creative and seasoned drug developer with 23 years of experience in escalating leadership roles in major global pharmaceutical companies. A clinical rheumatologist with a background in academic immunology research. Particular focus on drug discovery and pharmacological translation across multiple biologies and modalities. Passionate about innovation and efficient execution in translation and early clinical development, through novel endpoint and clinical program design. Expertise in auto-immune diseases, inflammation and in multiple rare disease therapeutic areas.Key contributions made to initiation of internal and external new target programs, biological rationale, disease alignment, regulatory data packages, clinical and translational plans for multiple candidate compounds (small molecule, biological and AAV), >15 FTIH programs, clinical lead for >12 PoC, and multiple exploratory clinical studies. Major contributions made to 3 products including Paxlovid; and 6 current Phase 3 development assets.KEY SKILLSETS/COMPETENCIES: •Multi-disciplinary line leadership: including physicians, clinical scientists, biologists, pharmacologists, pharmacokineticists, project leaders and chemists. Line groups between 12-60 people. Empowering, enabling style.•Program/Project leadership: leadership of LO, pre-clinical and clinical projects, of multiple modalities (small molecule, biological and gene therapy)•Matrix management: experienced leader of matrix groups with oversight of target identification and validation, lead optimisation, candidate selection and clinical phases. Chair of disease area science fora, clinical research and technical review committees.•Clinical insight: in depth knowledge of clinical features and pathophysiology of rheumatological, other autoimmune disease. Expertise in hematological, neurologic, cardiac and renal adult and pediatric rare diseases. Expertise in clinical and biomarker endpoint development, innovative Phase I/II clinical trial design•External interface management: Joint Steering committee leadership for 5 commercial external drug discovery alliances (small molecule, biologic, oligonucleotides and gene editing). Industry co-chairperson for Medical Research Council / ABPI consortium on early rheumatoid arthritis. JSC for cTAP consortium and drug development round table in DMD. Integration leadership of 2 company acquisitions. Leadership of pre-clinical gene therapy portfolio outlicensing.